Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
bisphosphonate-related osteonecrosis (441) 441
index medicus (344) 344
dentistry, oral surgery & medicine (318) 318
humans (315) 315
dentistry (294) 294
necrosis (221) 221
bones (217) 217
female (204) 204
osteonecrosis (195) 195
surgery (186) 186
male (185) 185
risk-factors (179) 179
zoledronic acid (178) 178
jaw (160) 160
aged (138) 138
bisphosphonates (138) 138
osteoporosis (132) 132
bone density conservation agents - adverse effects (130) 130
middle aged (125) 125
bisphosphonate-related osteonecrosis of the jaw (120) 120
diphosphonates - adverse effects (112) 112
cancer (106) 106
therapy (105) 105
animals (98) 98
cancer-patients (92) 92
bisphosphonate (88) 88
bone (88) 88
denosumab (86) 86
management (85) 85
prevention (83) 83
surgeons position paper (82) 82
risk factors (81) 81
american association (80) 80
analysis (80) 80
tooth extraction (68) 68
osteonecrosis of the jaw (67) 67
aged, 80 and over (65) 65
alendronate (65) 65
osteonecrosis - chemically induced (61) 61
rats (60) 60
health aspects (58) 58
multiple-myeloma (58) 58
bisphosphonate-associated osteonecrosis of the jaw - etiology (56) 56
care and treatment (55) 55
diphosphonates - administration & dosage (55) 55
bone density conservation agents - administration & dosage (54) 54
adult (53) 53
phosphonates (53) 53
retrospective studies (51) 51
bisphosphonate-associated osteonecrosis of the jaw - surgery (50) 50
treatment outcome (49) 49
imidazoles - adverse effects (47) 47
bisphosphonate-associated osteonecrosis of the jaw - pathology (46) 46
bone density conservation agents - therapeutic use (46) 46
bronj (46) 46
endocrinology & metabolism (46) 46
oncology (45) 45
jaws (42) 42
medication-related osteonecrosis (42) 42
abridged index medicus (41) 41
bisphosphonate-associated osteonecrosis of the jaw - diagnosis (41) 41
bisphosphonate-associated osteonecrosis of the jaw - therapy (40) 40
jaw diseases - chemically induced (40) 40
diphosphonates - therapeutic use (39) 39
osteoporosis - drug therapy (39) 39
mronj (38) 38
patients (38) 38
bisphosphonate-associated osteonecrosis of the jaw - diagnostic imaging (37) 37
medical research (37) 37
research (37) 37
in-vitro (36) 36
article (35) 35
association (35) 35
bone metastases (35) 35
diphosphonates - pharmacology (35) 35
imidazoles - administration & dosage (35) 35
medicine & public health (35) 35
pamidronate (35) 35
medicine, research & experimental (34) 34
wound healing (34) 34
drugs (33) 33
bisphosphonate-related osteonecrosis of the jaws (32) 32
disease models, animal (32) 32
medication-related osteonecrosis of the jaw (32) 32
medicine, experimental (32) 32
metastasis (32) 32
oral bisphosphonates (32) 32
bone density conservation agents - pharmacology (31) 31
diphosphonates (31) 31
postmenopausal women (31) 31
diagnosis (30) 30
mechanisms (30) 30
mice (30) 30
time factors (30) 30
biocompatibility (28) 28
follow-up studies (28) 28
orthopedics (28) 28
breast-cancer (27) 27
disease (27) 27
dental implants (26) 26
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (597) 597
Japanese (15) 15
Spanish (6) 6
German (5) 5
Korean (5) 5
French (3) 3
Hungarian (3) 3
Italian (3) 3
Portuguese (2) 2
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update
by Ruggiero, Salvatore L., DMD, MD and Dodson, Thomas B., DMD, MPH and Fantasia, John, DDS and Goodday, Reginald, DDS, MSc and Aghaloo, Tara, DDS, MD, PhD and Mehrotra, Bhoomi, MD and O'Ryan, Felice, DDS and American Association of Oral and Maxillofacial Surgeons
Journal of Oral and Maxillofacial Surgery, ISSN 0278-2391, 2014, Volume 72, Issue 10, pp. 1938 - 1956
Strategies for management of patients with, or at risk for, medication-related osteonecrosis of the jaw (MRONJ) were set forth in the American Association of... 
Surgery | ZOLEDRONIC ACID | BREAST-CANCER | JAW-LIKE DISEASE | RISK-FACTORS | MULTIPLE-MYELOMA PATIENTS | DENTISTRY, ORAL SURGERY & MEDICINE | BISPHOSPHONATE-RELATED OSTEONECROSIS | TOOTH EXTRACTION | RENAL-CELL CARCINOMA | LONG-TERM EFFICACY | CROSS-LINKING TELOPEPTIDE | Jaw Diseases - diagnosis | Neovascularization, Physiologic - drug effects | Humans | Jaw Diseases - therapy | Osteoporosis - drug therapy | Bone Remodeling - drug effects | Oral Surgical Procedures - adverse effects | Jaw Diseases - chemically induced | Patient Care Planning | Time Factors | Antineoplastic Agents - adverse effects | Angiogenesis Inhibitors - adverse effects | Osteonecrosis - diagnosis | Diagnosis, Differential | Osteonecrosis - therapy | Bone Density Conservation Agents - adverse effects | Risk Assessment | Risk Factors | Terminology as Topic | Neoplasms - drug therapy | Bone Resorption - prevention & control | Bisphosphonate-Associated Osteonecrosis of the Jaw - diagnosis | Bisphosphonate-Associated Osteonecrosis of the Jaw - therapy | Bisphosphonate-Associated Osteonecrosis of the Jaw - etiology | Osteonecrosis - chemically induced | Medical colleges | Strategic planning (Business) | Surgeons | Bones | College teachers | Trade and professional associations | Necrosis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology
by Fusco, Vittorio and Santini, Daniele and Armento, Grazia and Tonini, Giuseppe and Campisi, Giuseppina
Expert Opinion on Drug Safety, ISSN 1474-0338, 07/2016, Volume 15, Issue 7, pp. 925 - 935
Introduction: Osteonecrosis of the jaw (ONJ) is a clinically important, potentially painful and debilitating condition, which can affect the quality of life of... 
sunitinib | Bisphosphonate | everolimus | temsirolimus | aflibercept | Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) | bevacizumab | Osteonecrosis of the jaw (ONJ) | Medication-Related Osteonecrosis of the Jaw (MRONJ) | denosumab | RISK-FACTORS | AMERICAN ASSOCIATION | RENAL-CELL CARCINOMA | TYROSINE KINASE INHIBITORS | ZOLEDRONIC ACID | BREAST-CANCER | CANCER-PATIENTS | BISPHOSPHONATE-RELATED OSTEONECROSIS | SURGEONS POSITION PAPER | PHARMACOLOGY & PHARMACY | Jaw Diseases - diagnosis | Osteonecrosis - diagnosis | Risk Assessment - methods | Humans | Antineoplastic Agents - administration & dosage | Osteonecrosis - pathology | Molecular Targeted Therapy | Neoplasms - drug therapy | Jaw Diseases - chemically induced | Angiogenesis Inhibitors - administration & dosage | Jaw Diseases - pathology | Antineoplastic Agents - adverse effects | Bisphosphonate-Associated Osteonecrosis of the Jaw - pathology | Bisphosphonate-Associated Osteonecrosis of the Jaw - diagnosis | Quality of Life | Bisphosphonate-Associated Osteonecrosis of the Jaw - etiology | Osteonecrosis - chemically induced | Angiogenesis Inhibitors - adverse effects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Efficacy and safety of medical ozone (O3 ) delivered in oil suspension applications for the treatment of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: Preliminary results of a phase I–II study
by Ripamonti, Carla Ida and Cislaghi, Enrico and Mariani, Luigi and Maniezzo, Massimo
Oral Oncology, ISSN 1368-8375, 2011, Volume 47, Issue 3, pp. 185 - 190
Summary Osteonecrosis of the jaw (ONJ) is an adverse event that has been reported in patients receiving cancer treatment regimens, including bevacizumab,... 
Otolaryngology | Hematology, Oncology and Palliative Medicine | Bisphosphonates-related osteonecrosis of the jaw (BONJ) | Oil suspension of medical O 3 therapy | Curative treatment | Oil suspension of medical O | therapy | MULTIPLE-MYELOMA | RANDOMIZED-TRIAL | SKELETAL COMPLICATIONS | PREVENTIVE MEASURES | ZOLEDRONIC ACID | ONCOLOGY | DENTISTRY, ORAL SURGERY & MEDICINE | Oil suspension of medical O-3 therapy | PROSTATE-CANCER | BREAST-CANCER PATIENTS | DOUBLE-BLIND | LONG-TERM EFFICACY | AMERICAN-SOCIETY | Osteonecrosis - therapy | Prospective Studies | Bone Density Conservation Agents - adverse effects | Oils | Humans | Middle Aged | Jaw Diseases - therapy | Male | Treatment Outcome | Ozone - administration & dosage | Jaw Diseases - chemically induced | Female | Aged | Bone Neoplasms - drug therapy | Osteonecrosis - chemically induced | Administration, Topical | Diphosphonates - adverse effects | Suspensions
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Intraoral vacuum-assisted closure therapy – a pilot study in medication-related osteonecrosis of the jaw
by Laimer, Johannes, MD, DMD and Steinmassl, Otto, MD, DMD and Hechenberger, Martin, MD, DMD and Rasse, Michael, MD, DMD, PhD and Pikula, Rajmond, MD and Bruckmoser, Emanuel, MD, DMD
Journal of Oral and Maxillofacial Surgery, ISSN 0278-2391, 2017, Volume 75, Issue 10, pp. 2154 - 2161
Abstract Purpose For about two decades vacuum-assisted closure (V.A.C.®) therapy has been widely used for the management of complex wounds and soft tissue... 
Surgery | SURGERY | FOUNDATION | MANAGEMENT | PRESSURE WOUND THERAPY | DENTISTRY, ORAL SURGERY & MEDICINE | BISPHOSPHONATE-RELATED OSTEONECROSIS | EXPERIENCE | TOOTH EXTRACTION | SKIN | ASSOCIATION | Pilot Projects | Prospective Studies | Negative-Pressure Wound Therapy | Humans | Middle Aged | Bisphosphonate-Associated Osteonecrosis of the Jaw - therapy | Female | Male | Aged | Bones | Surgery, Plastic | Necrosis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Intraoperative efficiency of fluorescence imaging by Visually Enhanced Lesion Scope (VELscope® ) in patients with bisphosphonate related osteonecrosis of the jaw (BRONJ)
by Assaf, Alexandre T and Zrnc, Tomislav A and Riecke, Björn and Wikner, Johannes and Zustin, Jozef and Friedrich, Reinhard E and Heiland, Max and Smeets, Ralf and Gröbe, Alexander
Journal of Cranio-Maxillo-Facial Surgery, ISSN 1010-5182, 2013, Volume 42, Issue 5, pp. e157 - e164
Abstract Objectives The purpose of this study was to determine the potential of tissue fluorescence imaging by using Visually Enhanced Lesion Scope (VELscope®... 
Surgery | VELscope | Osteonecrosis | Fluorescence imaging | Bisphosphonates | Intraoperative visualization | MULTIPLE-MYELOMA | VISUALIZATION | SURGERY | RISK-FACTORS | MANAGEMENT | COMPLICATION | CLINICAL-FEATURES | CANCER-PATIENTS | VELscope (R) | DENTISTRY, ORAL SURGERY & MEDICINE | ORAL PREMALIGNANT LESIONS | SURGICAL RESECTION | BONE | Biopsy - methods | Prospective Studies | Follow-Up Studies | Humans | Fluorescence | Male | Mandibular Diseases - surgery | Maxillary Diseases - pathology | Tooth Extraction - methods | Bisphosphonate-Associated Osteonecrosis of the Jaw - pathology | Intraoperative Care | Doxycycline | Maxillary Diseases - surgery | Female | Mandibular Diseases - pathology | Aged | Fluorescent Dyes | Optical Imaging - methods | Bisphosphonate-Associated Osteonecrosis of the Jaw - surgery | Cohort Studies | Bones | Care and treatment | Necrosis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Double-layer closure techniques after bone surgery of medication-related osteonecrosis of the jaw – A single center cohort study
by Ristow, Oliver and Rückschloß, Thomas and Bodem, Jens and Bodem, Eva and Berger, Moritz and Kargus, Steffen and Engel, Michael and Hoffmann, Jürgen and Freudlsperger, Christian
Journal of Cranio-Maxillo-Facial Surgery, ISSN 1010-5182, 05/2018, Volume 46, Issue 5, pp. 815 - 824
Mucosal wound closure plays a key role after surgery of manifested medication-related osteonecrosis of the jaw (MRONJ). Additional soft tissue layers promise... 
Pedicled buccal fat flap | Therapy | Mylohyoideus muscle flap | BRONJ | MRONJ | Osteonecrosis of the jaw | SURGERY | STEM-CELLS | FAT PAD FLAP | AMERICAN ASSOCIATION | RESECTION | FOLLOW-UP | SURGICAL-MANAGEMENT | FLUORESCENCE | DENTISTRY, ORAL SURGERY & MEDICINE | BISPHOSPHONATE-RELATED OSTEONECROSIS | MAXILLA | POSITION PAPER | Medical research | Orthopedic surgery | Analysis | Medicine, Experimental | Bones | Health aspects | Methods | Necrosis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Photodynamic Inactivation of Actinomyces naeslundii in Comparison With Chlorhexidine and Polyhexanide—A New Approach for Antiseptic Treatment of Medication-Related Osteonecrosis of the Jaw?
by Hafner, Sigurd, MD, DMD and Ehrenfeld, Michael, MD, DMD and Storz, Enno, MD and Wieser, Andreas, MD
Journal of Oral and Maxillofacial Surgery, ISSN 0278-2391, 2016, Volume 74, Issue 3, pp. 516 - 522
Purpose Local antimicrobial therapy is a fundamental principle in the treatment of lesions of medication-related osteonecrosis of the jaw. Antimicrobial... 
Surgery | LOCAL-DRUG DELIVERY | METHYLENE-BLUE | IN-VITRO | ANTIINFECTIVE THERAPY | PERIODONTITIS | DENTISTRY, ORAL SURGERY & MEDICINE | BISPHOSPHONATE-RELATED OSTEONECROSIS | RANDOMIZED CLINICAL-TRIAL | ORAL INFECTIONS | MECHANISMS | PERI-IMPLANTITIS | Biguanides - pharmacology | Microbial Viability - drug effects | Photosensitizing Agents - therapeutic use | Actinomyces - drug effects | Anti-Infective Agents, Local - pharmacology | Photochemotherapy - methods | Humans | Lasers, Semiconductor - therapeutic use | Chlorhexidine - pharmacology | Bacterial Load - drug effects | Bisphosphonate-Associated Osteonecrosis of the Jaw - microbiology | Methylene Blue - therapeutic use | Fluorescent Dyes | Analysis | Cyclohexane | Bones | Chlorhexidine | Drug therapy | Health aspects | Necrosis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw
by Yoneda, Toshiyuki and Hagino, Hiroshi and Sugimoto, Toshitsugu and Ohta, Hiroaki and Takahashi, Shunji and Soen, Satoshi and Taguchi, Akira and Nagata, Toshihiko and Urade, Masahiro and Shibahara, Takahiko and Toyosawa, Satoru and Japanese Allied Committee on Osteonecrosis of the Jaw
Journal of Bone and Mineral Metabolism, ISSN 0914-8779, 1/2017, Volume 35, Issue 1, pp. 6 - 19
Antiresorptive agent-related osteonecrosis of the jaw (ARONJ) is an intractable, though rare, complication in cancer patients with bone metastases and patients... 
Drug holidays | Medicine & Public Health | Orthopedics | Osteonecrosis of the jaw | Metabolic Diseases | Denosumab | Bisphosphonates | Oral bacterial infection | Team therapeutic approaches | MEDICINE, RESEARCH & EXPERIMENTAL | RISK-FACTORS | MANAGEMENT | QUESTIONNAIRE-BASED SURVEY | ZOLEDRONIC ACID | CANCER-PATIENTS | MEDICATION-RELATED OSTEONECROSIS | BISPHOSPHONATE-RELATED OSTEONECROSIS | ENDOCRINOLOGY & METABOLISM | TOOTH EXTRACTION | OSTEOPOROSIS TREATMENT | Asian Continental Ancestry Group | Humans | Japan | Bisphosphonate-Associated Osteonecrosis of the Jaw - diagnosis | Bisphosphonate-Associated Osteonecrosis of the Jaw - therapy | Female | Male | Evidence-Based Medicine | Periodicals as Topic | Practice Guidelines as Topic | Bones | Necrosis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Evaluation of the Treatment Strategies for Medication‐Related Osteonecrosis of the Jaws (MRONJ) and the Factors Affecting Treatment Outcome: A Multicenter Retrospective Study with Propensity Score Matching Analysis
by Hayashida, Saki and Soutome, Sakiko and Yanamoto, Souichi and Fujita, Shigeyuki and Hasegawa, Takumi and Komori, Takahide and Kojima, Yuka and Miyamoto, Hironori and Shibuya, Yasuyuki and Ueda, Nobuhiro and Kirita, Tadaaki and Nakahara, Hirokazu and Shinohara, Mitsuyo and Umeda, Masahiro
Journal of Bone and Mineral Research, ISSN 0884-0431, 10/2017, Volume 32, Issue 10, pp. 2022 - 2029
ABSTRACT Medication‐related osteonecrosis of the jaw (MRONJ) is an adverse event that may inhibit the treatment of primary disease and remarkably influence the... 
MEDICATION‐RELATED OSTEONECROSIS OF THE JAWS (MRONJ) | DENTAL BIOLOGY | TUMOR‐INDUCED BONE DISEASE | CLINICAL TRIALS | OSTEOPOROSIS | MEDICATION-RELATED OSTEONECROSIS OF THE JAWS (MRONJ) | TUMOR-INDUCED BONE DISEASE | MANAGEMENT | THERAPY | BISPHOSPHONATE-RELATED OSTEONECROSIS | ENDOCRINOLOGY & METABOLISM | PREVENTION | SINGLE-CENTER | Multivariate Analysis | Propensity Score | Bisphosphonate-Associated Osteonecrosis of the Jaw - pathology | Humans | Risk Factors | Female | Male | Treatment Outcome | Aged | Retrospective Studies | Wound Healing | Bisphosphonate-Associated Osteonecrosis of the Jaw - surgery | Bones | Patient outcomes | Analysis | Necrosis | Jaw | Osteonecrosis | Surgery | Quality of life
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Osteonecrosis of the jaw and the role of macrophages
by Pazianas, Michael
Journal of the National Cancer Institute, ISSN 0027-8874, 02/2011, Volume 103, Issue 3, pp. 232 - 240
Nitrogen-containing bisphosphonates have been associated with the development of osteonecrosis of the jaws (ONJ), but the lack of reliable epidemiological data... 
MULTIPLE-MYELOMA | ZOLEDRONIC ACID | IN-VITRO | RISK-FACTORS | ONCOLOGY | BEAGLE DOGS | NITROGEN-CONTAINING BISPHOSPHONATES | BISPHOSPHONATE-RELATED OSTEONECROSIS | BONE | PREVALENCE | AUTOSOMAL-DOMINANT OSTEOPETROSIS | Jaw Diseases - diagnosis | Osteonecrosis - epidemiology | Humans | Jaw Diseases - prevention & control | Osteomyelitis - chemically induced | Antibodies, Monoclonal - adverse effects | Tomography, X-Ray Computed | Positron-Emission Tomography | Antineoplastic Agents - administration & dosage | Osteonecrosis - metabolism | Jaw Diseases - metabolism | Jaw Diseases - chemically induced | Mouth Mucosa - drug effects | RANK Ligand - immunology | Antibodies, Monoclonal, Humanized | Antineoplastic Agents - adverse effects | Etidronic Acid - adverse effects | Pyrroles - adverse effects | Vitamin D - administration & dosage | Risedronate Sodium | Diphosphonates - adverse effects | Etidronic Acid - analogs & derivatives | RANK Ligand - adverse effects | Osteonecrosis - diagnosis | Radiography, Panoramic | Osteonecrosis - etiology | Bone Density Conservation Agents - adverse effects | Macrophages - pathology | Imidazoles - adverse effects | Jaw Diseases - etiology | Risk Factors | Diphosphonates - administration & dosage | Denosumab | Jaw Diseases - epidemiology | Mevalonic Acid - metabolism | Monocytes - drug effects | Magnetic Resonance Imaging | Alendronate - adverse effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Indoles - adverse effects | Signal Transduction - drug effects | Macrophages - drug effects | Osteonecrosis - chemically induced | Osteonecrosis - prevention & control | Diphosphonates - pharmacology | Osteoclasts - drug effects | Complications and side effects | Diphosphonates | Physiological aspects | Bones | Research | Macrophages | Risk factors | Necrosis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text OPG‐Fc but Not Zoledronic Acid Discontinuation Reverses Osteonecrosis of the Jaws (ONJ) in Mice
by de Molon, Rafael Scaf and Shimamoto, Hiroaki and Bezouglaia, Olga and Pirih, Flavia Q and Dry, Sarah M and Kostenuik, Paul and Boyce, Rogely W and Dwyer, Denise and Aghaloo, Tara L and Tetradis, Sotirios
Journal of Bone and Mineral Research, ISSN 0884-0431, 09/2015, Volume 30, Issue 9, pp. 1627 - 1640
ABSTRACT Osteonecrosis of the jaws (ONJ) is a significant complication of antiresorptive medications, such as bisphosphonates and denosumab. Antiresorptive... 
ZOLEDRONIC ACID | ALVEOLAR BONE | BISPHOSPHONATES | OSTEOCLASTS | DENOSUMAB | OSTEONECROSIS OF THE JAW (ONJ) | ANTIRESORPTIVES | alveolar bone | antiresorptives | zoledronic acid | osteoclasts | bisphosphonates | denosumab | osteonecrosis of the jaw (ONJ) | RISK-FACTORS | INDUCE OSTEONECROSIS | NITROGEN-CONTAINING BISPHOSPHONATES | BONE-RESORPTION | POSTMENOPAUSAL OSTEOPOROSIS | CANCER-PATIENTS | CLINICAL-APPLICATIONS | BISPHOSPHONATE-RELATED OSTEONECROSIS | ENDOCRINOLOGY & METABOLISM | EXPERIMENTAL PERIODONTITIS | KAPPA-B LIGAND | RANK Ligand - metabolism | Recombinant Fusion Proteins - pharmacology | Tartrate-Resistant Acid Phosphatase | Male | Mandible - diagnostic imaging | X-Ray Microtomography | Acid Phosphatase - metabolism | Isoenzymes - metabolism | Diphosphonates - therapeutic use | Disease Models, Animal | Bone Resorption | Maxilla - diagnostic imaging | Mice, Inbred C57BL | Osteoprotegerin - pharmacology | Abscess | Rats | Imidazoles - pharmacology | Osteoclasts - metabolism | Animals | RANK Ligand - antagonists & inhibitors | Bisphosphonate-Associated Osteonecrosis of the Jaw - pathology | Immunoglobulin Fc Fragments - pharmacology | Mice | Denosumab - pharmacology | Bisphosphonate-Associated Osteonecrosis of the Jaw - drug therapy | Diphosphonates - pharmacology | Osteoporosis | Bones | Phosphonates | Necrosis | Animal models | Zoledronic acid | Mandibles | Osteonecrosis | Acid phosphatase (tartrate-resistant) | TRANCE protein | Acid phosphatase | Bisphosphonates | Osteoprotegerin | Metastases
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Bisphosphonate-Related Osteonecrosis of the Jaws–An Initial Case Series Report of Treatment Combining Partial Bone Resection and Autologous Platelet-Rich Plasma
by Curi, Marcos Martins, DDS, MSc, PhD and Cossolin, Giuliano Saraceni Issa, DDS, MSc, PhD and Koga, Daniel Henrique, DDS, MSc, PhD and Zardetto, Cristina, DDS, MSc, PhD and Christianini, Silmara, MD and Feher, Olavo, MD and Cardoso, Camila Lopes, DDS, MSc and Oliveira dos Santos, Marcelo, MD
Journal of Oral and Maxillofacial Surgery, ISSN 0278-2391, 2011, Volume 69, Issue 9, pp. 2465 - 2472
Purpose Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a well-recognized pathologic entity that is challenging and difficult to manage. Recent... 
Surgery | DIAGNOSIS | SUPPORT | CANCER-PATIENTS | RISK-FACTORS | DENTISTRY, ORAL SURGERY & MEDICINE | FIBRIN GLUE | SURGICAL-MANAGEMENT | OUTCOMES | AVASCULAR NECROSIS | HISTORY | Injections, Intravenous | Bone Density Conservation Agents - adverse effects | Humans | Middle Aged | Bone Neoplasms - secondary | Male | Treatment Outcome | Diphosphonates - administration & dosage | Bone Density Conservation Agents - administration & dosage | Jaw Diseases - chemically induced | Osteonecrosis - surgery | Aged, 80 and over | Adult | Female | Platelet-Rich Plasma | Aged | Bone Neoplasms - drug therapy | Osteonecrosis - chemically induced | Jaw Diseases - surgery | Diphosphonates - adverse effects | Bones | Necrosis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights